Axa’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Axa’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-211,448	Closed	-$4.26M	–	1312
2021 Q3	$4.26M	Sell	211,448 -66,020	-24%	-$1.82M	0.01%	724
2021 Q2	$10.4M	Sell	277,468 -93,972	-25%	-$2.88M	0.03%	500
2021 Q1	$9.5M	Buy	371,440 +6,249	+2%	+$160K	0.03%	528
2020 Q4	$8.04M	Buy	365,191 +90,532	+33%	+$1.99M	0.03%	574
2020 Q3	$4.94M	Buy	274,659 +47,243	+21%	+$978K	0.02%	626
2020 Q2	$5.78M	Sell	227,416 -11,456	-5%	-$247K	0.02%	573
2020 Q1	$4.39M	Buy	+238,872	New	+$4.64M	0.02%	553

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Axa's DRNA Position: Q4 2021 in Review

Axa sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 211,448 shares — an estimated $4.26M sold.

Axa first reported a position in DRNA in Q1 2020 and held it in 7 quarters. The position peaked at $10.4M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Axa reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Axa sold 211,448 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $4.26M.
Axa first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2020 and held it in 7 quarters.
Axa's Dicerna Pharmaceuticals, Inc. position peaked at $10.4M in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Axa's 13F filing for Q4 2021, filed 14 Feb 2022.